What is the current share price of AstraZeneca Pharma India Limited (ASTRAZEN)?

As of the latest market update, AstraZeneca Pharma India Limited (ASTRAZEN) is trading at ₹8,249.5. The stock has moved 0.26% up in the recent session.

What is the technical sentiment for ASTRAZEN stock?

Based on our proprietary technical analysis, the current signal for ASTRAZEN is "SELL". This analysis considers over 20+ indicators including RSI, MACD, and moving average crossovers to gauge market momentum.

What is the 52-week high and low for AstraZeneca Pharma India Limited?

AstraZeneca Pharma India Limited has seen a 52-week high of ₹10,691 and a 52-week low of ₹7,551.5. Comparing the current price to these levels helps investors understand the stock's relative valuation and volatility over the past year.

Which sector does AstraZeneca Pharma India Limited belong to?

AstraZeneca Pharma India Limited operates in the Healthcare sector, specifically within the Pharmaceuticals & Biotechnology industry. Its performance is often influenced by broader trends in the Healthcare segment.

What is the market capitalization of ASTRAZEN?

AstraZeneca Pharma India Limited (ASTRAZEN) has a market capitalization of approximately ₹20.62K Cr. This classifies it as a small cap stock in the Indian market.

ASTRAZEN

NSE

AstraZeneca Pharma India Limited (SMALL CAP)

Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals

₹8,249.50

21.00 (0.26%)

High VOLATILITY

As on 12 Jun 2026

Advanced Chart

Price History

Market Cap

The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.

₹20.62K Cr

SMALL CAP

P/E Ratio

Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.

109.7

Industry

The specific business sector the company operates in. Useful for comparing with similar companies.

Pharmaceuticals

52-Week Range

The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.

52W Low₹7,551.5+9.2%

52W High₹10,691-22.8%

Current Price

₹8,249.50

Circuit Limits (20%)

The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.

Lower Circuit₹6,599.60

Upper Circuit₹9,899.40

Reference Price

₹8,249.50

Investment Checklist

Triple Top on 1D (BREAKOUT CONFIRMED) — target ₹8482.5

Head and Shoulders on 1D (BREAKOUT CONFIRMED) — target ₹7914.5

Composite score -42.09 (SELL) with 84.6% confidence

Trend: Price below most MAs — downtrend

10/20 Bearish Cross detected 3 day(s) ago

Technical Analysis

Analysis from 2026-06-12

Confidence

85%

Trend

BEARISH

Price below most MAs — downtrend

EMA20

8473.82

EMA50

8469.18

EMA200

8690.59

Price Action

MIXED

NEUTRAL

Higher Highs1

Higher Lows4

Lower Highs8

Lower Lows5

Support & Resistance Levels

Resistance (Above)

₹8354.50

₹8679.50

₹8900.00

₹9211.33

₹9456.50

Support (Below)

₹8232.50

₹7998.75

₹7677.00

₹7551.50

Volume Analysis

TrendDECREASING

Change-64.00%

Unusual VolumeNo

Recent MA Crossovers

10/20 Bearish Cross

3 days ago

SELL

Stop Loss Levels

Fixed Risk

1% Risk₹8167.01

3% Risk₹8002.01

5% Risk₹7837.02

7% Risk (Custom)

₹7672.03

Technical Levels

1x ATR (Volatility)₹8002.33

2x ATR (Swing)₹7755.16

3x ATR (Trend)₹7507.99

Immediate Support₹8232.50

Financials

Financial Analysis

Metric	Mar '25	Jun '25	Sep '25	Dec '25
Revenue	₹477.5 Cr	₹526.3 Cr	₹559.1 Cr	₹611.6 Cr
Net Profit	₹58.3 Cr	₹55.8 Cr	₹54.2 Cr	₹32.6 Cr
EPS	—	₹22.33	₹21.69	₹13.04
Operating Profit	₹96.8 Cr	₹92 Cr	₹76.1 Cr	₹51.4 Cr

Peer Comparison

Pharmaceuticals

Peer Comparison

Symbol	Name	Price	Change
SUNPHARMA	Sun Pharmaceutical Industries Limited	₹1,807.70	+0.75%
DIVISLAB	Divi's Laboratories Limited	₹6,638.00	-0.26%
TORNTPHARM	Torrent Pharmaceuticals Limited	₹4,571.20	-0.02%
CIPLA	Cipla Limited	₹1,389.40	+0.44%
ZYDUSLIFE	Zydus Lifesciences Limited	₹1,104.70	-0.11%
DRREDDY	Dr. Reddy's Laboratories Limited	₹1,275.40	-0.05%
LUPIN	Lupin Limited	₹2,293.30	+0.88%
MANKIND	Mankind Pharma Limited	₹2,381.10	+0.35%
AUROPHARMA	Aurobindo Pharma Limited	₹1,472.80	+0.59%
LAURUSLABS	Laurus Labs Limited	₹1,394.30	+0.25%

Corporate Information

Large Deals

View All

Bulk, Block and Short deals reported for this stock.

Loading Deals...

Corporate Actions

Recent actions

View All

Ex Date	Purpose	Type
18 Jul 2025	Dividend - Rs 32 Per Share	DIVIDEND
05 Jul 2024	Dividend - Rs 24 Per Share	DIVIDEND
14 Jul 2023	Dividend - Rs 16 Per Share	DIVIDEND
07 Jul 2022	Dividend - Rs 8 Per Share	DIVIDEND
18 Aug 2021	Interim Dividend - Rs 2 Per Share	INTERIM_DIVIDEND

Announcements

Latest updates

View All

Date	Description	Link
13 Jun 2026	Resignation of Director/KMP/SMP
12 Jun 2026	General Updates
11 Jun 2026	General Updates
09 Jun 2026	Disclosure under SEBI Takeover Regulations
04 Jun 2026	Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

Board Meetings

Upcoming and past meetings

View All

Date	Purpose	Links
26 May 2026	Board Meeting Intimation	XBRL
26 May 2026	Financial Results/Dividend
11 Feb 2026	Board Meeting Intimation	XBRL
11 Feb 2026	Financial Results
07 Nov 2025	Board Meeting Intimation	XBRL

Corporate Events

Upcoming results & meetings

View All

No upcoming events found

We couldn't find any scheduled corporate actions for this symbol at the moment.

Shareholding Pattern

As of Dec 2025

Current Distribution

Trend (Last 8 Qtrs)

Latest News

News for ASTRAZEN

View All

AstraZeneca Pharma India gets CDSCO nod for expanded use of breast cancer drug Enhertu

negative

CNBC TV18 - Markets 2d ago

AstraZeneca Pharma India gets CDSCO nod for expanded use of breast cancer drug Enhertu

The approval expands the eligible patient population for the therapy in India and allows AstraZeneca to market the drug for the additional indication, subject to any other required statutory clearances.

ASTRAZENHealthcare

Read full story

AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer

neutral

ET Markets - Industry 2d ago

AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer

AstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its import, sale, and distribution for an additional use. The drug will now be available as a first-line treatment for certain types of advanced breast cancer. This development expands treatment options for oncologists and patients facing HER2-positive breast cancer.

ASTRAZENSPARCHealthcare

Read full story

positive

Business Standard - Markets 17d ago

AstraZeneca Pharma shares slip 6% on posting 23% fall in Q4 profit YoY

In the March quarter, AstraZeneca Pharma reported a 23 per cent year-on-year (Y-o-Y) decline in consolidated net profit to ₹44.9 crore, from ₹58.25 crore a year ago

ASTRAZENHealthcare

Read full story

ASTRAZEN

Price History

Investment Checklist

Technical Analysis

Technical Analysis

Trend

Price Action

Support & Resistance Levels

Volume Analysis

Recent MA Crossovers

Stop Loss Levels

Fixed Risk

Technical Levels

Financials

Financial Analysis

Peer Comparison

Peer Comparison

Corporate Information

Large Deals

Corporate Actions

Announcements

Board Meetings

Corporate Events

Shareholding Pattern

Shareholding Pattern

Current Distribution

Trend (Last 8 Qtrs)

Latest News

News for ASTRAZEN

AstraZeneca Pharma India gets CDSCO nod for expanded use of breast cancer drug Enhertu

AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer

AstraZeneca Pharma shares slip 6% on posting 23% fall in Q4 profit YoY

Frequently Asked Questions

What is the current share price of AstraZeneca Pharma India Limited (ASTRAZEN)?

What is the technical sentiment for ASTRAZEN stock?

What is the 52-week high and low for AstraZeneca Pharma India Limited?

Which sector does AstraZeneca Pharma India Limited belong to?

What is the market capitalization of ASTRAZEN?